Endocannabinoid and ceramide levels are altered in patients with colorectal cancer

Chen,Ling; Chen,Huixia; Li,Yanting; Li,Lei; Qiu,Yan; Ren,Jie

doi:10.3892/or.2015.3973

Endocannabinoid and ceramide levels are altered in patients with colorectal cancer

Authors:
- Ling Chen
- Huixia Chen
- Yanting Li
- Lei Li
- Yan Qiu
- Jie Ren
View Affiliations

Affiliations: Department of Medical Sciences, Medical College, Xiamen University, Xiamen 361102, P.R. China
Published online on: May 12, 2015 https://doi.org/10.3892/or.2015.3973
Pages: 447-454

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Endocannabinoids and ceramides have demonstrated growth inhibition, cell death induction and pro-apoptotic activity in cancer research. In the present study, we describe the profiles of two major endocannabinoids, ceramides, free fatty acids and relevant metabolic enzymes in 47 pairs of human colorectal cancer tissues and adjacent non-tumor tissues. Among them, anandamide (AEA) and its metabolite, arachidonic acid (AA), were markedly upregulated in cancer tissues particularly in those with lymphatic metastasis. The levels of C16 and C24 ceramides were significantly elevated in the colorectal tumor tissues, while levels of C18 and C20 ceramides showed opposite trends. Levels of two enzymes participating in the biosynthesis and degradation of AEA, N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NPLD) and fatty acid amide hydrolase (FAAH), together with the most abundant ceramide synthases (CerS1, CerS2, CerS5 and CerS6) in the colon were also determined. Quantitative-PCR analysis indicated that the mRNA levels of these enzymes were overexpressed in the tumor tissues. The activities of NPLD and FAAH were also upregulated. In addition, both gene and protein expression levels of cannabinoid receptor 1 (CB1) were elevated but not of CB2. Elevation of AEA and alteration of ceramides (C16, C24, C18, C20) may qualify as potential endogenous biomarkers and novel drug targets for colorectal cancer.

View Figures

View References

1	Veldkamp R, Gholghesaei M, Bonjer HJ, Meijer DW, Buunen M, Jeekel J, Anderberg B, Cuesta MA, Cuschierl A, Fingerhut A, et al: European Association of Endoscopic Surgery (EAES): Laparoscopic resection of colon Cancer: Consensus of the European Association of Endoscopic Surgery (EAES). Surg Endosc. 18:1163–1185. 2004. View Article : Google Scholar : PubMed/NCBI
2	Tsujimoto H, Tsukioka S, Ono S, Sakamoto E, Sakamoto K, Tsuta K, Nakagawa F, Saito H, Uchida J, Kiniwa M, et al: Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Oncol Lett. 1:973–980. 2010.PubMed/NCBI
3	Yang SY, Miah A, Sales KM, Fuller B, Seifalian AM and Winslet M: Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment. Int J Oncol. 38:1695–1702. 2011.PubMed/NCBI
4	Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al: Identification of an endogenous 2-mono-glyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:83–90. 1995. View Article : Google Scholar : PubMed/NCBI
5	Devane WA, Breuer A, Sheskin T, Järbe TU, Eisen MS and Mechoulam R: A novel probe for the cannabinoid receptor. J Med Chem. 35:2065–2069. 1992. View Article : Google Scholar : PubMed/NCBI
6	Di Carlo G and Izzo AA: Cannabinoids for gastrointestinal diseases: Potential therapeutic applications. Expert Opin Investig Drugs. 12:39–49. 2003. View Article : Google Scholar : PubMed/NCBI
7	De Petrocellis L, Cascio MG and Di Marzo V: The endocannabinoid system: A general view and latest additions. Br J Pharmacol. 141:765–774. 2004. View Article : Google Scholar : PubMed/NCBI
8	Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 4:873–884. 2003. View Article : Google Scholar : PubMed/NCBI
9	Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA and Gilula NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:83–87. 1996. View Article : Google Scholar : PubMed/NCBI
10	Pertwee RG: Cannabinoid Receptors. Academic Press; New York, NY: 1995
11	Pertwee RG: Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 74:129–180. 1997. View Article : Google Scholar : PubMed/NCBI
12	Di Marzo V, Melck D, De Petrocellis L and Bisogno T: Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat. 61:43–61. 2000. View Article : Google Scholar : PubMed/NCBI
13	Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D and Hipkin RW: Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Mol Pharmacol. 57:1045–1050. 2000.PubMed/NCBI
14	Guzmán M: Cannabinoids: Potential anticancer agents. Nat Rev Cancer. 3:745–755. 2003. View Article : Google Scholar : PubMed/NCBI
15	Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D’argenio G, Scaglione G, Bifulco M, Sorrentini I, et al: Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 125:677–687. 2003. View Article : Google Scholar : PubMed/NCBI
16	Sarnataro D, Grimaldi C, Pisanti S, Gazzerro P, Laezza C, Zurzolo C and Bifulco M: Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett. 579:6343–6349. 2005. View Article : Google Scholar : PubMed/NCBI
17	De Petrocellis L, Melck D, Palmisano A, Bisogno T, Laezza C, Bifulco M and Di Marzo V: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA. 95:8375–8380. 1998. View Article : Google Scholar : PubMed/NCBI
18	Contassot E, Wilmotte R, Tenan M, Belkouch MC, Schnüriger V, de Tribolet N, Burkhardt K and Dietrich PY: Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol. 63:956–963. 2004.PubMed/NCBI
19	Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M and Guzmán M: Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 6:313–319. 2000. View Article : Google Scholar : PubMed/NCBI
20	Morad SA and Cabot MC: Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 13:51–65. 2013. View Article : Google Scholar
21	Grösch S, Schiffmann S and Geisslinger G: Chain length-specific properties of ceramides. Prog Lipid Res. 51:50–62. 2012. View Article : Google Scholar
22	Selzner M, Bielawska A, Morse MA, Rüdiger HA, Sindram D, Hannun YA and Clavien PA: Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 61:1233–1240. 2001.PubMed/NCBI
23	Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, Haimovitz-Friedman A, Fuks Z and Kolesnick R: 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res. 58:2260–2264. 1998.PubMed/NCBI
24	Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J and Weichselbaum RR: Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 57:1270–1275. 1997.PubMed/NCBI
25	Verheij M, van Blitterswijk WJ and Bartelink H: Radiation-induced apoptosis - the ceramide-SAPK signaling pathway and clinical aspects. Acta Oncol. 37:575–581. 1998. View Article : Google Scholar
26	Chen L, Xie B, Li L, Jiang W, Zhang Y, Fu J, Guan G and Qiu Y: Rapid and sensitive LC-MS/MS analysis of fatty acids in clinical amples. Chromatographia. 77:1241–1247. 2014. View Article : Google Scholar
27	Wu X, Han L, Zhang X, Li L, Jiang C, Qiu Y, Huang R, Xie B, Lin Z, Ren J, et al: Alteration of endocannabinoid system in human gliomas. J Neurochem. 120:842–849. 2012. View Article : Google Scholar
28	D’Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I and Di Marzo V: Upregulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 20:568–570. 2006.
29	Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, et al: Endocannabinoid Research Group: Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med Berl. 86:89–98. 2008. View Article : Google Scholar
30	Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M and Di Marzo V: Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology. 141:118–126. 2000.
31	Cianchi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, Messerini L, Manera C, Ronconi E, Romagnani P, et al: Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res. 14:7691–7700. 2008. View Article : Google Scholar : PubMed/NCBI
32	Sánchez C, Galve-Roperh I, Rueda D and Guzmán M: Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Δ⁹-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol. 54:834–843. 1998.
33	Ogretmen B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 4:604–616. 2004. View Article : Google Scholar : PubMed/NCBI
34	Koybasi S, Senkal CE, Sundararaj K, Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM, Hannun YA, et al: Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem. 279:44311–44319. 2004. View Article : Google Scholar : PubMed/NCBI
35	Seumois G, Fillet M, Gillet L, Faccinetto C, Desmet C, François C, Dewals B, Oury C, Vanderplasschen A, Lekeux P, et al: De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis. J Leukoc Biol. 81:1477–1486. 2007. View Article : Google Scholar : PubMed/NCBI
36	White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L and Voelkel-Johnson C: Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene. 28:1132–1141. 2009. View Article : Google Scholar : PubMed/NCBI
37	Osawa Y, Uchinami H, Bielawski J, Schwabe RF, Hannun YA and Brenner DA: Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem. 280:27879–27887. 2005. View Article : Google Scholar : PubMed/NCBI
38	Senkal CE, Ponnusamy S, Bielawski J, Hannun YA and Ogretmen B: Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J. 24:296–308. 2010. View Article : Google Scholar :
39	Cairns RA, Harris IS and Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
40	Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. Cancer Res. 70:8117–8126. 2010. View Article : Google Scholar : PubMed/NCBI
41	Nashed M, Chisholm JW and Igal RA: Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells. Exp Biol Med. 237:1007–1017. 2012. View Article : Google Scholar